6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
March 2018 in “International journal of basic and clinical pharmacology” Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
29 citations
,
August 2007 in “Annals of Oncology” Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
10 citations
,
June 2019 in “Dermatologic therapy” DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.
44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
More research is needed to understand chemotherapy-induced hair loss and its phases.
1 citations
,
January 2012 in “Türk jinekoloji ve obstetrik derneði dergisi/Türk Jinekoloji ve Obstetrik Derneği dergisi” Most patients experienced significant but reversible hair loss during treatment.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
39 citations
,
May 2004 in “Clinics in Dermatology” The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
April 2025 in “Journal of Pharma Insights and Research.” Females had more chemotherapy side effects than males, with many being preventable.
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
December 2025 in “Current Issues in Molecular Biology” Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.
September 2023 in “Journal of the American Academy of Dermatology”
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
1 citations
,
January 2024 in “The Journal of Dermatology” Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
March 2016 in “Oncology Times” Insurers opposed ASCO's recommendation for a single cancer care pathway program.
September 2020 in “Journal of Education Health and Sport” Personalized treatment and teamwork among doctors can reduce chemotherapy side effects and improve patient outcomes.
5 citations
,
January 2024 in “Egyptian Dental Journal /Egyptian Dental Journal” Anti-cancer drugs are diverse and hard to classify due to their different forms and actions.